Top Cancer Treatment Research Will Be Presented at ASTRO’s Annual Meeting
American Society for Radiation Oncology (ASTRO)Five webcast news briefings to highlight innovative studies.
Five webcast news briefings to highlight innovative studies.
Men with prostate cancer in Texas may be driving more than three times farther than needed to obtain radiation oncology treatments for their cancer when treated at a urology-owned radiation oncology practice versus other facilities, according to a study to be published online August 15, 2012, and in the September 1, 2012, print issue of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
The American Society for Radiation Oncology (ASTRO) will release the results of its online member survey conducted earlier this month. ASTRO CEO Laura Thevenot and radiation oncologist Connie Mantz, MD, will detail the survey results and the expected impact that the proposed 15 percent Medicare cuts to radiation oncology could have on cancer care across the country. This survey was in response to reimbursement cuts for radiation oncology services proposed on July 6, 2012, by the Centers for Medicare and Medicaid Services (CMS).
Accelerated whole breast irradiation after lumpectomy is an effective treatment for ductal carcinoma in situ (DCIS), a very common early stage and noninvasive form of breast cancer, meaning many more breast cancer patients could see their treatment times reduced by half, according to a study in the June issue of the International Journal of Radiation Oncology•Biology•Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).
The American Society for Radiation Oncology (ASTRO) has selected J. Robert Cassady, MD, FASTRO, George T.Y. Chen, PhD, FASTRO, and Mark W. Dewhirst, DVM, PhD, FASTRO, as the Society’s 2012 Gold Medal recipients. Drs. Cassady, Chen and Dewhirst will be recognized with this honor at an Awards Ceremony held during ASTRO’s 54th Annual Meeting taking place October 28-31, 2012, at the Boston Convention and Exhibition Center in Boston.
The American Society for Radiation Oncology (ASTRO) has been honored with a Communicator Award for its work on the fall 2011 edition of ASTROnews. This publication was recognized with an Award of Distinction and awarded the Silver Communicator Award.
The American Society for Radiation Oncology (ASTRO) has been honored with two 2012 Hermes Creative Awards from the Association of Marketing and Communication Professionals (AMCP) for its work on the fall 2011 edition of ASTROnews and the Radiation Therapy for Cancer brochure. This is the sixth year in a row that ASTRO has received Hermes Awards.
Despite past safety concerns, the antioxidant supplement beta-carotene, is safe to use during radiation therapy treatments for prostate cancer and does not increase the risk of prostate cancer death or metastases, according to a study in the May issue of the International Journal of Radiation Oncology•Biology•Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Surgeons are not always including radiation oncologists early enough in a patient’s treatment decision-making process, leaving some patients uninformed of all of their treatment options and potentially leading to more mastectomies over breast-conserving therapy, according to a study in the April issue of the International Journal of Radiation Oncology•Biology•Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Breast cancer patients treated with intensity modulated radiation therapy (IMRT) instead of standard whole breast irradiation (WBI) have a lower incidence of acute or chronic toxicities, according to a study in Practical Radiation Oncology (PRO), the official clinical practice journal of the American Society for Radiation Oncology (ASTRO).
The American Society for Radiation Oncology (ASTRO) has developed a guideline on the radiotherapeutic and surgical management for newly diagnosed brain metastases. It has been published in Practical Radiation Oncology (PRO), ASTRO’s official clinical practice journal.
Patients treated with IMRT for head and neck cancer report an increasingly better quality of life post-treatment when compared to patients receiving other forms of radiation therapy, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.
Slight temperature increases of the oral mucus membranes early in a head and neck cancer patient’s chemotherapy and radiation therapy (chemoradiotherapy) treatment is a predictor of severe mucositis later in treatment, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.
A select subgroup of advanced head and neck cancer patients treated with radiation therapy plus the chemotherapy drug cisplatin had more positive outcomes than patients treated with radiation therapy alone and continued to show positive results 10 years post-treatment, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.
Oral HPV infection is more common among men than women, explaining why men are more prone than women to develop an HPV related head and neck cancer, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.
In Denmark, implementing a national fast track system for cancer patients reduced the waiting time between a patient’s initial meeting with a health care provider and their first treatment by four weeks when comparing 2010 to 2002, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.
Radiation therapy with or without chemotherapy is less effective for patients with HIV when compared to the recurrence and overall survival rates in patients who do not have HIV, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.
Head and neck cancers respond well to the anti-cancer drug erlotinib when it is administered before surgery and a stronger dose is given to patients who smoke, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.
Routine use of positron emission tomography/computed tomography (PET/CT) scans in head and neck cancer patient follow-up can detect local recurrences before they become clinically apparent and may improve the outcome of subsequent salvage therapy, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.
The Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM, will host two news briefings on top head and neck cancer research from its meeting January 26-28, 2012, in Phoenix.
Proton therapy, a type of external beam radiation therapy, is a safe and effective treatment for prostate cancer, according to two new studies published in the January issue of the International Journal of Radiation Oncology•Biology•Physics (Red Journal), the American Society for Radiation Oncology’s (ASTRO) official scientific journal.
Anthony Zietman, MD, FASTRO, an endowed professor of radiation oncology at Harvard Medical School in Boston, officially began his tenure as editor of the International Journal of Radiation Oncology•Biology•Physics (Red Journal), the American Society for Radiation Oncology’s (ASTRO) primary research journal, on January 1.
The American Society for Radiation Oncology (ASTRO) has hired Nadine Eads as director of quality improvement. Eads will lead the newly formed Quality Improvement Department as ASTRO continues its efforts to promote quality improvement across the specialty.
When cancer patients are given the choice, they are significantly more likely to use Web-based technology to answer questions about their quality of life six months after treatment, compared to a paper survey, according to a unique study presented at a scientific session, October 5, 2011, at the 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
A higher dose of radiation (74 Gy) does not improve overall survival for non-small cell lung cancer that has spread to the lymph nodes, compared to the standard radiation dose (60 Gy), according to an interim analysis of a late-breaking randomized study presented at the plenary session, October 3, 2011, at the 53rdAnnual Meeting of the American Society for Radiation Oncology (ASTRO).
More than three-quarters of cancer patients have insufficient levels of vitamin D (25-hydroxy-vitamin D) and the lowest levels are associated with more advanced cancer, according to a study presented on October 2, 2011, at the 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
While the majority (70 percent) of surveyed cancer care physicians initiate contact with the bereaved family and caregivers of their patients who have died, over two-thirds do not feel they have received adequate training in this area during their residency or fellowship, according to a study presented October 2, 2011, at the 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
A shorter course of radiation treatment that delivers higher doses of radiation per day in fewer days (hypofractionation) is as effective in decreasing intermediate to high-risk prostate cancer from returning as conventional radiation therapy at five years after treatment, according to a randomized trial presented at the plenary session, October 3, 2011, at the 53rdAnnual Meeting of the American Society for Radiation Oncology (ASTRO).
Men with localized prostate cancer treated with a newer technology, intensity modulated radiation therapy (IMRT), have more than a quarter (26 percent) fewer late bowel and rectal side effects and a statistically improved lower dose of radiation to the bladder and rectum, compared to those who undergo 3D-CRT, according to a randomized study presented at the plenary session October 3, 2011, at the 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Rectal cancer patients who use a new combination of the chemotherapy, Capecitabine, together with five weeks of radiation (50 Gy) before surgery have an 88 percent chance of surviving the cancer three years after treatment, according to randomized trial presented at the plenary session, October 3, 2011, at the 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Journalists are invited to register for ASTRO’s 53rd Annual Meeting: “Patient-focused, High-quality, Multidisciplinary Care.”
Adding hormone therapy to radiation therapy has been proven in randomized clinical trials to improve overall survival for men with intermediate- and high-risk prostate cancer. However, adding hormone therapy may reduce overall survival in men with pre-existing heart conditions, even if they have high-risk prostate cancer according to a new study just published online in advance of print in the International Journal of Radiation Oncology•Biology•Physics, the official scientific journal of ASTRO.
Intensity modulated radiation therapy, a newer, more precise form of radiation therapy, causes fewer gastrointestinal side effects when combined with hormone therapy than using three-dimensional radiation therapy, according to a study published in the June issue of the International Journal of Radiation Oncology•Biology•Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).
The American Society for Radiation Oncology (ASTRO) has selected K. Kian Ang, MD, PhD, FASTRO, and Bernard Cummings, MB, ChB, FASTRO, as the Society’s 2011 Gold Medal recipients. Drs. Ang and Cummings will be recognized with this honor at the Awards Ceremony held during ASTRO’s 53rd Annual Meeting taking place October 2-6, 2011, in Miami Beach, Fla.
Combining computerized tomography (CT) with fluorodeoxyglucose positron emission tomography (FDG-PET) images results in significantly more defined tumor outlines and potentially different treatment options in head and neck cancer patients compared to using CT alone, according to research presented today, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North America (RSNA).
Proton radiography imaging used prior to and during proton treatments for pediatric cancer patients provides for more accurate treatment delivery and a lower dose of radiation compared to standard diagnostic X-rays and cone beam CT, according to a study presented today at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. The symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North America (RSNA).
A pelvic MRI scan with IV contrast and rectal balloon is highly effective in identifying local recurrence even at low PSA values in prostate cancer patients with a rising or persistently elevated PSA after prostatectomy, according to a study presented April 29, 2011, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. The symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North America (RSNA).
An annual mammogram is sufficient follow-up after breast conserving therapy (BCT) for breast cancer patients, according to a study presented today, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO) and Radiological Society of North America (RSNA).
Injecting a tissue spacer in the prostate-rectal inter-space is an effective way to reduce the rectal dose for prostate cancer patients receiving radiation therapy, according to research presented April 30, 2011, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO) and Radiological Society of North America (RSNA).
The American Society for Radiation Oncology (ASTRO) has developed a guideline for the use of external beam radiation therapy, endobronchial brachytherapy and concurrent chemotherapy to palliate thoracic symptoms caused by advanced lung cancer. The guideline will be published in Practical Radiation Oncology, an official journal of ASTRO.
The American Society for Radiation Oncology (ASTRO) Clinical Affairs and Quality Committee has developed a guideline for the use of radiation therapy in treating bone metastases. The guideline will be published in the International Journal of Radiation Oncology•Biology•Physics, an official journal of ASTRO
Smokers who continue to smoke while undergoing radiation treatments for head and neck cancer fare significantly worse than those who quit smoking before therapy, according to a study in the February issue of the International Journal of Radiation Oncology•Biology•Physics, an official journal of the American Society for Radiation Oncology (ASTRO).
The American Society for Radiation Oncology (ASTRO) has named Anthony Zietman, M.D., an endowed professor of radiation oncology at Harvard Medical School in Boston, as the new editor of the International Journal of Radiation Oncology•Biology•Physics, ASTRO’s primary research journal also known as the Red Journal.
Radiation oncologists can enhance patient safety in their clinics by further developing a culture of safety in which all team members are alerted to the possibility of errors and can work together to maximize safety, according to an invited article in the inaugural issue of Practical Radiation Oncology (PRO), a new medical journal whose mission is to improve the quality of radiation oncology practice. PRO is an official journal of the American Society for Radiation Oncology (ASTRO).
The American Society for Radiation Oncology (ASTRO) is pleased to announce it has published its first issue of Practical Radiation Oncology (PRO), a new medical journal whose mission is to improve the quality of radiation oncology practice. Published by leading scientific publisher Elsevier, the issue is both available in print and online at www.practicalradonc.org.
HIV-positive head and neck cancer patients respond well to radiation therapy treatments and experience similar toxicity rates as non-HIV-positive patients, despite prior reports to the contrary, according to a study in the January issue of the International Journal of Radiation Oncology•Biology•Physics, an official journal of the American Society for Radiation Oncology (ASTRO).
The American Society for Radiation Oncology (ASTRO) has received a 2010 Web Health Award for its patient-geared website, www.rtanswers.org.
New data shows that people exposed to the mineral erionite found in the gravel of road materials in North Dakota may be at significantly increased risk of developing mesothelioma, a type of lung cancer most often associated with asbestos exposure, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.
Cancer researchers have identified six gene markers present in early stage non-small cell lung cancer (NSCLC) that show promise in helping oncologists better identify which tumors will relapse after curative surgery, according to a study presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.
Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.